Relationship between lymphocytemonocyte ratio and prognosis of malignant tumors

doi:10.3760/cma.j.issn.1673-422X.2016.10.011

Abstract

Abstract: Related studies have been confirmed that tumorassociated inflammation is associated with tumor progression and prognosis in a variety of tumors. As an inflammatory biomarker, lymphocytemonocyte ratio shows significant value in predicting the prognosis of malignant tumors. It can not only be appropriate for patients with cancer risk stratification, but also provide the basis for the subsequent development of individualized treatment programs.

Key words: Lymphocytes, Monocytes, Neoplasms, Prognosis

Qian Menlong, Lu Ning. Relationship between lymphocytemonocyte ratio and prognosis of malignant tumors[J]. Journal of International Oncology, 2016, 43(10): 769-771.

References

［1］ Landskron G, De la Fuente M, Thuwajit P, et a1. Chronic inflammation and cytokines in the tumor microenvironment［J］. J Immunol Res, 2014, 2014: 149185. DOI: 10.1155/2014/149185. ［2］ Zhang J, Huang SH, Li H, et a1. Preoperative lymphocyte count is a favorable prognostic factor of diseasefree survival in nonsmallcell lung cancer［J］. Med Oncol, 2013, 30(1): 352. DOI: 10.1007/s1203201203523. ［3］ Botta C, Barbieri V, Ciliberto D, et a1. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced nonsmall cell lung cancer patients［J］. Cancer Biol Ther, 2013, 14(6): 469-475. DOI: 10.4161/cbt.24425. ［4］ Li J, Jiang R, Liu WS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocytetomonocyte ratio with favorable prognosis in nasopharyngeal carcinoma［J］. PLoS One, 2013, 8(12): e83069. DOI: 10.1371/journal.pone.0083069. ［5］ Li YL, Pan YY, Jiao Y, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard firstline regimens［J］. Ann Hematol, 2014, 93(4): 617-626. DOI: 10.1007/s0027701319169. ［6］ Jiang R, Cai XY, Yang ZH, et al. Elevated peripheral blood lymphocytetomonocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma［J］. Chin J Cancer, 2015, 34(6): 237-246. DOI: 10.1186/s4088001500257. ［7］ Lin GN, Peng JW, Xiao JJ, et al. Prognostic impact of circulating monocytes and lymphocytetomonocyte ratio on previously untreated metastatic nonsmall cell lung cancer patients receiving platinumbased doublet［J］. Med Oncol, 2014, 31(7): 70. DOI: 10.1007/s1203201400700. ［8］ Hu P, Shen H, Wang G, et al. Prognostic significance of systemic inflammationbased lymphocytemonocyte ratio in patients with lung cancer: based on a large cohort study［J］. PLoS One, 2014, 9(9): e108062. DOI: 10.1371/journal.pone.0108062. ［9］ Go SI, Kim RB, Song HN, et al. Prognostic significance of the lymphocytetomonocyte ratio in patients with small cell lung cancer［J］. Med Oncol, 2014, 31(12): 323. DOI: 10.1007/s120320140323y. ［10］ Chen YM, Lai CH, Chang HC, et al. Baseline and trend of lymphocytetomonocyte ratio as prognostic factors in epidermal growth factor receptor mutant nonsmall cell lung cancer patients treated with firstline epidermal growth factor receptor tyrosine kinase inhibitors［J］. PLoS One, 2015, 10(8): e0136252. DOI: 10.1371/journal.pone.0136252. ［11］ Amedei A, Benagiano M, della Bella C, et al. Novel immunotherapeutic strategies of gastric cancer treatment［J］. J Biomed Biotechnol, 2011, 2011: 437348. DOI: 10.1155/2011/437348. ［12］ Zhou X, Du Y, Xu J, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage Ⅱ/Ⅲ gastric cancer［J］. Tumour Biol, 2014, 35(11): 11659-11666. DOI: 10.1007/s132770142504x. ［13］ Deng Q, He B, Liu X, et al. Prognostic value of preoperative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model［J］. J Transl Med, 2015, 13: 66. DOI: 10.1186/s1296701504090. ［14］ Ozawa T, Ishihara S, Kawai K, et al. Impact of a lymphocyte to monocyte ratio in stage Ⅳ colorectal cancer［J］. J Surg Res, 2015, 199(2): 386-392. DOI: 10.1016/j.jss.2015.06.014. ［15］ Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage Ⅲ colon cancer［J］. Br J Cancer, 2014, 110(2): 435-440. DOI: 10.1038/bjc.2013.785. ［16］ Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscleinvasive and metastatic bladder cancer: summary of the 2013 guidelines［J］. Eur Urol, 2014, 65(4): 778-792. DOI: 10.1016/j.eururo.2013.11.046. ［17］ Kitamura H, Tsukamoto T, Shibata T, et al. Randomised phase Ⅲ study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscleinvasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209［J］. Ann Oncol, 2014, 25(6): 1192-1198. DOI: 10.1093/annonc/mdu126. ［18］ Temraz S, Mukherji D, Farhat ZA, et al. Preoperative lymphocytetomonocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis［J］. BMC Urol, 2014, 14: 76. DOI: 10.1186/147124901476. ［19］ Yoshida T, Kinoshita H, Yoshida K, et al. A novel risk stratification model, involving preoperative lymphocytemonocyte ratio and standard pathological factors, for overall survival in patients with bladder cancer undergoing radical cystectomy［J］. Jpn J Clin Oncol, 2015, 45(12): 1162-1167. DOI: 10.1093/jjco/hyv146.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.